Source: Frontiers in Medicine, by Wu, Jiao; Wang, Dengchao; Ye, Wanping; He, Juan; Jiang, Yayun (August 27, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- The review examines nanomaterials that improve optical signals, catalytic amplification, target enrichment, and sensor interfaces in pathogen point-of-care tests.
- It covers lateral flow assays, biosensors, microfluidic systems, and isothermal nucleic acid amplification for respiratory, urinary, and fecal samples.
- Clinical accuracy, real-world deployment, and independent validation of integrated nanomaterial-enabled systems remain to be established.
Jiao Wu and colleagues survey how nanomaterials, materials engineered at extremely small scales, could strengthen point-of-care testing for infectious pathogens. The review focuses on diagnostic tools that can be used at or near a patient rather than only in a central laboratory. That goal matters because conventional tests often force a trade-off between speed, accuracy, cost, and portability. Culture methods can identify living microbes and support antibiotic susceptibility testing, but they can take too long for immediate decisions. Immunoassays are fast and comparatively simple, yet their sensitivity can vary, especially when a sample contains little pathogen material. Molecular methods such as real-time quantitative polymerase chain reaction, or PCR, can be highly sensitive and specific but commonly require specialized instruments and trained personnel. Nanomaterials may help close these gaps by making weak biological signals easier to capture, amplify, and read. The review maps their potential roles across lateral flow strips, biosensors, microfluidic chips, and nucleic acid amplification systems, while emphasizing their relevance to respiratory, urinary, and fecal samples.
Why pathogen testing still has gaps
Every diagnostic strategy starts by looking for a different clue. Culture-based testing grows a pathogen from a clinical sample, which can confirm that living organisms are present and can enable testing of which antibiotics may work. The drawback is time: organisms must grow before they can be identified, an awkward delay when clinicians need to make treatment and infection-control choices quickly.
Immunoassays look for the molecular fingerprints of infection, often using the highly selective binding between an antigen and an antibody. Antigens are molecules associated with a pathogen, while antibodies are immune proteins that recognize particular targets. These tests can be inexpensive and easy to operate, which makes them useful for front-line screening, but low pathogen levels and complicated clinical samples can make reliable detection difficult.
What nanomaterials add
A useful analogy is a faint radio signal: a receiver works better when its antenna captures more of the signal and its circuitry makes that signal loud enough to hear. Nanomaterials can act as both the antenna and the amplifier in a diagnostic device. Their small size, large surface area, and distinctive optical, electrical, or catalytic properties can improve how a test captures a target and converts that event into a visible or measurable result.
Wu and colleagues organize these functions into four broad roles: optical signal output, catalytic signal amplification, target enrichment, and interfacial regulation. Optical output means that a nanoparticle can help generate or strengthen a color, fluorescence, or other light-based signal. Catalytic amplification uses a material to speed reactions that produce a detectable readout. Target enrichment concentrates scarce pathogen material from a larger sample, while interfacial regulation improves the crucial contact zone where a biological target meets a sensor surface.
From test strips to chip-based systems
Lateral flow immunoassays are the familiar strip-format tests in which liquid moves across a membrane and a line appears when a target is captured. Their appeal is straightforward operation and rapid results, but conventional strips can struggle to detect low-abundance pathogens or quantify how much target is present. Nanomaterials could sharpen the visual signal or provide a measurable output, helping convert an essentially yes-or-no format into one with greater analytical detail.
The review also considers biosensors, microfluidic systems, and isothermal nucleic acid amplification platforms. A biosensor turns a biological recognition event into a readable signal, while a microfluidic chip guides tiny volumes of liquid through miniature channels, much like plumbing reduced to the scale of a small device. Isothermal amplification copies target genetic material at a constant temperature, potentially avoiding the repeated heating and cooling required by PCR. Combining these approaches with nanomaterials could support more integrated tests that handle samples, recognize targets, amplify signals, and report results in a compact workflow.
Three ways to recognize an infection
The review identifies three major recognition routes for nanomaterial-assisted pathogen testing. The first is pathogen surface recognition, in which a test captures molecules or structures displayed on the outside of a bacterium, virus, or other microorganism. The second uses reactive oxygen species, or ROS, highly reactive oxygen-containing molecules, to convert recognition into a signal. The third is nucleic acid recognition, which detects a pathogen by identifying a characteristic DNA or RNA sequence.
Each route addresses a different diagnostic challenge. Surface recognition can support rapid antigen-style testing, while nucleic acid recognition can provide a highly specific genetic signature. ROS-mediated signal conversion offers another way to translate a hard-to-see biological interaction into a measurable readout. The relevant specimen also matters: respiratory samples, urine, and fecal material each carry their own mix of cells, proteins, chemicals, and microbes that can interfere with detection or make rare targets harder to find.
Why This Matters
Fast, dependable pathogen detection affects more than the individual test result. It can guide timely treatment, help limit unnecessary antibiotic use, and support public-health responses when infections spread. The COVID-19 pandemic exposed how quickly diagnostic bottlenecks can become system-wide problems, especially when laboratories, trained staff, and sophisticated instruments are not readily available. Portable tests with stronger sensitivity and better quantitative accuracy could be particularly valuable in primary care, remote settings, and outbreak response.
The promise is not that one nanomaterial or one device will replace every laboratory method. Culture remains important for recovering live pathogens and assessing antimicrobial susceptibility, and molecular testing remains a key reference approach for many infections. Instead, the central opportunity is to design point-of-care tools that preserve the practical simplicity of rapid tests while improving their ability to find scarce targets in real clinical samples.
Future progress will depend on turning these material-level capabilities into dependable diagnostic workflows that work beyond controlled settings. The most useful systems will need to combine sample preparation, target recognition, signal generation, and clear result reporting without adding excessive complexity. If those elements can be integrated successfully, nanomaterial-enabled point-of-care testing could give clinicians and public-health teams faster information when timing matters most.